go to contents go to 1depth menu

Heal the World,
Better Life

This is our value.

HISTORY

Development of hepatitis B vaccine 'HEPACCINE-B'
We entered the global market with the hepatitis B vaccine `HEPACCINE-B` developed by using only locally developed technology.
Entering the fluids business
We greatly improved the treatment environment by launching safe-flex IV solutions (bag fluids) for the first time in Korea.
'CONDITION' opened the anti-hangover drinks market for the first time in Korea.
CONDITION has held the title of No.1 anti-hangover drink in the market for 25 years since its first introduction in Korea. It is spreading a new hangover-easing culture beyond Korea in China, Vietnam and Japan.
Development of the EPO formulation 'EPOKINE' for the first time in Korea and the third time in the world
CJ HealthCare Corp. is leading the localization of drugs through continuous R&D.
Launching the fixed dose combination IMD for hypertension 'EXONE'
EXONE is the fixed dose combination IMD for hypertension applied with amlodipine adipate developed by CJ HealthCare Corp.
Launching the fixed dose combination IMD for hypertension 'MACHKHAN'
CJ HealthCare Corp. is improving the quality of patients' lives by launching MACHKHAN, a combination of candesartan and amlodipine, for the first time in Korea.
  • 1986Development of 'HEPACCINE-B'
  • 1992Entering the fluids business
  • 1992Launching CONDITION
  • 1998Development of EPOKINE
  • 2013Launching EXONE
  • 2016Launching MACHKHAN

PRODUCTS

CJ HealthCare seeks to improve the quality of life by developing new drugs and biologicals.

R&D

Based on R&D capability and platform technology, we are expanding the research areas and creating tangible achievements. View more

BUSINESS

We always try to provide customers the new value of health. View more